Oncology Blue Book Part 2 Flashcards
what causes myelosuppression
can be a result of disease or chemotherapy due to siping out own body’s cells in bone marrow
aetiology of myelosuppression
treatment related –> cytotoxic and biological agent, causes a transient fall of leukocytes and platelet count in conventional dose but worse in higher dose
bone marrow infiltration –> infiltration of malignant cells into the bone marrow and cause pancytopenia
para-neoplastic syndrome –> syndrome caused by the production of hormone/cytokines by tumour cells leading to an immune response by the body leading to depletion of leukocytes etc
other –> anaemia caused by a tumor and chemotherapy
when does myelosuppression usually come on
10-12 days post inital engagement of chemotherapy
which cancer more likely to cause bone marrow infiltration
lung breast prostate (those cancer in particular that invade bones)
haematological cancer –> leukomai, lymphoma etc
which type of myelosuppression does carboplatin cause
thrombocytopenia
which biological agents causes myelossuppression
interforon
interleukin-2
Ix for myelosuppression
full evaluation incl blood film, measurement of haematinics, bone marrow aspirate and trephine (bone marrow test)
treatment for myelosuppression due to anaemia
gold standard = transfusion but the loss of risks
recombinant erythropoietin –> stimulate EPO and so stimulate RBC production from bone marrow level
what level of HB is considered to be impairing QOL
< 10 g/dl
presentation of thrombocytopenia
petechial haemorrhage, spontaneous nose bleeds, corneal haemorrhage, haematuria
what level of platlet is considered life-threatening
< 10x10(9)/L –> significant risk of spontaneous risk of bleeding eg intra-cerebral haemorrhage
treatment of thrombocytopenia when platelet level of < 10x10 9
urgent platelet transfusion
what platelet support is given when HB level between 10-20x10 (9)
frequent transfusion of platelet but not urgent
treatment of thrombocytopenia when platelet is > 20x10 (9)
usually nothing unless spontanoues bleeding
what can repeat platelet transfusion cause
specifice antibbodies produced by the body itself targeting the transfused platelet
using of a singler donor or a donor with HLA matched platelet
what level of WBC is considered to be infection prone
< 1x10(9)/L
management of a patient present with fever post chemo
medical emergency due to the possbility of neutropenic sepsis
board spectrum ABx - local Leeds guideline –> Tazosine
what examination should be avoided in patients presentation consistent of neutropenic sepsis
PR or vaginal exam to avoid any breach to the mucosa leading to the infection risk
management of persistent pyrexia despite correct Abx treatment
additional anti-fungal or anti-viral agents
treatment of pneumocystis pneumonia
co-trimoxazole
what are some of the prevention method of myelosuppression
prophylactic ABx –> only used in those pt with myelosuppression and other co-morbidity leading to inc infection risk eg COPD and risk of pneumonia
dose modifications –> red dose of chemo = dec severity of myelosuppression
colony stimulating factors –> current no evidence to prove the effectiveness of this treatment
what are some of the novel discovery in recent biological therapy
1) further understanding of the biological process of tumour formation
2) pathway which tumour cells subverting the immune system of the body